Abata Therapeutics

Abata co-founder and advisor Richard Ransohoff on the need in Progressive MS and ABA-101’s potential. ABA-101 may significantly benefit patients with Progressive MS who currently lack adequate treatment options. In preclinical studies, ABA-101 was shown to be safe and demonstrated tissue-specific trafficking, persistence, and robust suppression of inflammation, supporting its potential therapeutic effect. bit.ly/3LiotOa

Abata CEO Samantha Singer comments on the IND clearance of ABA-101, which validates our approach to leveraging Tregs to treat autoimmune diseases. Most importantly, it’s a potentially life-changing treatment for patients with Progressive MS. bit.ly/3LiotOa

We’re excited to announce IND clearance of ABA-101 for Progressive Multiple Sclerosis (MS). It’s the first open IND for our best-in-class autologous TCR-Treg cell therapy platform. We expect to initiate our Phase 1 study later this year. This is an important milestone for us and for patients. ABA-101 was specifically designed to benefit Progressive MS patients who have no or insufficient treatment options today. bit.ly/3LiotOa

We recently celebrated our 3-year Abataversary! In that time, we’ve advanced groundbreaking research, forged valuable partnerships, and grown our world-class team – all with the aim of bringing transformational therapies to patients. We look forward to continuing that momentum – and having a lot of fun while we’re doing it. #anniversary #team #culture

We were recently ranked #2 on the Inspiring Workplaces Group’s “Top 100” list for 2024. The award is based on 6 criteria: Culture & Purpose, Leadership, Wellbeing, Inclusion, Employee Voice, and Employee Experience. We are tremendously proud of the team that has brought us here. Thank you to Inspiring Workplaces for the recognition. We remain steadfast in our focus on the health of people living with autoimmune diseases and in our commitment to the health and happiness of our employees.

Great article from David Hallal at ElevateBio on how their Foundry Model works. We know firsthand how effective this model can be, as our collaboration with ElevateBio accelerated the development of our manufacturing process for our Treg therapies and helped shave an entire year off our initial IND timeline, saving us valuable time and resources. Perhaps even more importantly, that process serves as a template for our future development programs, including our second program for the treatment of Type 1 diabetes. Thanks to Elevate for including us in their write-up.

Next week Devan Moodley will present on discovering T cell receptor (TCR)-engineered Tregs for the treatment of autoimmune diseases. We hope to see you at the meeting! #Tregs #celltherapy #MS

This week both our CSO Ellen Cahir-McFarland and CMO Leonard Dragone will speak at the 6th Annual Treg Summit in Boston. We look forward to seeing our colleagues in the field and discussing some of our work with them. #Tregs #celltherapy

We recently participated in the #WalkMS Boston, where we had a wonderful team turnout and were one of the top fundraisers. This event is near and dear to us given our mission to provide an improved treatment option for progressive #multiplesclerosis patients. It was wonderful being with the community and we look forward to next year!

At the AAN 2024 Annual Meeting, Jefte Drijvers, our Director of BD and Program Leadership, will give a presentation on the preclinical work supporting our lead program, ABA-101, for the treatment of progressive #MS. We hope to see you at #AANAM, #AAN2024!